Specify a stock or a cryptocurrency in the search bar to get a summary
CanBas Co Ltd
4575CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. Address: 2-2-1, Otemachi, Numazu, Japan, 410-0801
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4575
Dividend Analytics 4575
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4575
Stock Valuation 4575
Financials 4575
Results | 2019 | Dynamics |